Sodium Oligomannate for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Sodium Oligomannate for Health & Longevity

Created on 06/27/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A seaweed-derived sugar compound thought to work through the gut, reshaping bacteria to quiet brain inflammation. In mild-to-moderate Alzheimer's disease, a 36-week study found a real but modest memory-and-thinking improvement, with reassuring short-term safety. There are no data at all in healthy adults. (Full Review)

Protocol

Standard Dose
900 mg/day
Oral, as 450 mg twice daily (commonly 150 mg capsules); the only regimen with controlled efficacy data.
Dosing Schedule
Split, twice daily
Morning and evening, driven by the ~11-hour half-life rather than circadian considerations.
Sourcing
China-approved product only
The genuine, regulator-approved Chinese product through legitimate channels; avoid grey-market import to prevent counterfeit or adulterated product.
Time to effect
Cognitive Signal
As early as week 4
Separation from placebo on the cognitive scale appeared by week 4 and was sustained — within weeks rather than many months.

Benefits

Contraindications
  • Pregnant or breastfeeding individuals
  • Children
  • Known hypersensitivity to the compound or to marine-algae-derived products
  • Significant pre-existing liver disease (Child-Pugh Class B–C)
  • Unexplained hematuria
    •
Key Interactions
  • Prescription drugs (cholinesterase inhibitors: donepezil, rivastigmine, galantamine; memantine)
  • Over-the-counter medications that broadly alter the gut environment
  • Supplements (probiotics, prebiotics, fiber)
  • Additive: gut-microbiome or neuroinflammation modulators (certain probiotics, anti-inflammatory agents)
  • Antibiotics (broad-spectrum)
    •

Risk & Side Effects

  • High: Generally comparable overall adverse-event burden
    •
  • Medium: [risks_medium]
    •
  • Low: Minor specific adverse events; unknown long-term and off-label safety
    •
  • Speculative: Theoretical microbiome-disruption risks
    •

Monitoring

Marker Target Why
ALT / AST (liver enzymes) ALT ~10–26 U/L; AST ~10–26 U/L Detect the small risk of liver-enzyme elevation seen in trials
LDL cholesterol <100 mg/dL (optimal <80 mg/dL) Catch the minor LDL increase observed with the drug
Urinalysis (red blood cells) No hematuria (negative for blood) Screen for the small hematuria signal noted in trials
ADAS-cog or MMSE (cognitive score) Stable or improving from baseline Track the primary outcome the drug targets
Fasting lipid panel (full) Per standard optimal targets Context for any LDL change and overall cardiometabolic status

Cadence: Baseline before starting, reassess at ~4–12 weeks, then every 3–6 months while continuing.

Qualitative Assessment

  • Cognitive clarity and memory: changes in memory, orientation, and day-to-day functioning
  • Behavioral and mood symptoms: any change in agitation, apathy, or neuropsychiatric symptoms
  • Energy and daily-living ability: ability to carry out routine activities
  • Gastrointestinal tolerance: any change in gut symptoms
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.